1Y Close · As of Aug 26, 2026
Eutilex operates in the Pharmaceuticals sector.
Legal name: Eutilex Co.,Ltd.
In fiscal year 2025, Eutilex (263050) reported revenue of 10.3 billion KRW, up 8.1% from 9.5 billion KRW a year earlier.
Operating profit was -18.9 billion KRW and net income was -25.8 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 35.3 billion KRW, with a P/B of 2.24.
These figures can be verified in the DART filing (receipt no. 20260327001702).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 10.3B | -18.9B | -25.8B |
| 2024 | 9.5B | -26.5B | -29.5B |
| 2023 | 132M | -29.8B | -28.3B |
Recent Filings
Litigation Ruling
기타시장안내 (투자주의 환기종목 지정 사유 추가 관련 시장조치 미진)
Semi-Annual Review Adverse Opinion (Capital Erosion 50%+ or Equity Below 1B)
Checks
4 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-19 | Litigation Ruling |
| 2026-08-14 | 기타시장안내 (투자주의 환기종목 지정 사유 추가 관련 시장조치 미진) |
| 2026-08-14 | Semi-Annual Review Adverse Opinion (Capital Erosion 50%+ or Equity Below 1B) |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-12 | Proxy Solicitation Reference |